PCH
VRTX icon

PGIM Custom Harvest’s Vertex Pharmaceuticals VRTX Stock Holding History

PGIM Custom Harvest’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$404K Sell
814
-466
-36% -$207K 0.01% 212
2026
Q1 		$572K Buy
1,280
+34
+3% +$15.9K 0.01% 165
2025
Q4 		$565K Sell
1,246
-2
-0.2% -$862 0.01% 159
2025
Q3 		$489K Buy
1,248
+28
+2% +$11.7K 0.01% 165
2025
Q2 		$543K Sell
1,220
-24
-2% -$11.1K 0.01% 143
2025
Q1 		$603K Buy
1,244
+7
+0.6% +$3.26K 0.01% 138
2024
Q4 		$498K Sell
1,237
-132
-10% -$61.2K 0.01% 162
2024
Q3 		$637K Buy
1,369
+235
+21% +$113K 0.01% 144
2024
Q2 		$532K Buy
1,134
+434
+62% +$188K 0.01% 140
2024
Q1 		$293K Buy
700
+63
+10% +$26.6K 0.01% 170
2023
Q4 		$259K Buy
637
+16
+3% +$5.91K 0.01% 162
2023
Q3 		$216K Buy
621
+9
+1% +$3.15K 0.01% 163
2023
Q2 		$215K Buy
+612
New +$206K 0.01% 163

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PGIM Custom Harvest's VRTX Position: Q2 2026 in Review

PGIM Custom Harvest reduced its Vertex Pharmaceuticals (VRTX) stake by 36% in Q2 2026, selling an estimated $207K and leaving 814 shares worth $404K. The position accounts for 0.01% of the portfolio, ranked #212.

PGIM Custom Harvest first reported a position in VRTX in Q2 2023 and has held it in 13 quarters since. The position peaked at $637K in Q3 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • PGIM Custom Harvest held 814 shares of Vertex Pharmaceuticals worth $404K as of Q2 2026.
  • PGIM Custom Harvest sold 466 Vertex Pharmaceuticals shares in Q2 2026, an estimated $207K.
  • Vertex Pharmaceuticals made up 0.01% of PGIM Custom Harvest's portfolio in Q2 2026, its #212 holding.
  • PGIM Custom Harvest first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • PGIM Custom Harvest's Vertex Pharmaceuticals position peaked at $637K in Q3 2024.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on PGIM Custom Harvest's 13F filing for Q2 2026, filed 13 Aug 2026.